KCTV: Saint Luke’s Launches Global Clinical Trial to Investigate Potential COVID-19 Treatment

Saint Luke’s Mid America Heart Institute launches a global clinical trial to investigate whether the diabetes drug dapagliflozin could be a treatment for patients with COVID-19.  Dr. Mikhail Kosiborod, Saint Luke's cardiologist, is serving as the principal investigator for the study which will enroll 900 patients globally.

Related Content

KMBC: Worldwide clinical drug trial for COVID-19 led by a doctor at Saint Luke's
Apr. 25, 2020

KMBC: Worldwide clinical drug trial for COVID-19 led by a doctor at Saint Luke's
As the entire world comes together to attempt to find a vaccine and treatments for this global pandemic, it is exciting that an international trial of this nature was created and is being led by doctors and researchers here in Kansas City.
Blue sphere COVID-19 viruses
Apr. 25, 2020

Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in COVID-19 patients.